

SECURITIES AND EXCHANGE COMMISSION

SEC FORM 17-Q

QUARTERLY REPORT PURSUANT TO SECTION 17 OF THE SECURITIES
REGULATION CODE AND SRC RULE 17(2)(b) THEREUNDER

1. For the quarterly period ended ...**March 31, 2026**
2. Commission Identification Number. **CS201423451** 3. BIR Tax Identification No. **008-917-666**

Allied Care Experts (ACE) Medical Center – Tacloban, Inc.

4. Exact name of issuer as specified in its charter

Leyte, Philippines

5. Province, country or other jurisdiction of incorporation or organization

6. Industry Classification Code: se Only)

7. Address of issuer's principal office Postal Code
Barangay 78, Marasbaras, Tacloban City, Leyte **6500**

8. Issuer's telephone number, including area code
(053) 888-4322 / 0956-461-4352

9. Former name, former address and former fiscal year, if changed since last report

10. Securities registered pursuant to Sections 8 and 12 of the Code, or Sections 4 and 8 of the RSA

Title of each Class	Number of shares of common stock outstanding and amount of debt outstanding
COMMON SHARE, P1,000 PAR VALUE	208,700 shs / Php580,210,301
FOUNDER SHARE, P1,000 PAR VALUE	600 shs

11. Are any or all of the securities listed on a Stock Exchange?

Yes [] No [✓]

If yes, state the name of such Stock Exchange and the class/es of securities listed therein:

12. Indicate by check mark whether the registrant:

(a) has filed all reports required to be filed by Section 17 of the Code and SRC Rule 17 thereunder or Sections 11 of the RSA and RSA Rule 11(a)-1 thereunder, and Sections 26 and 141 of the Corporation Code of the Philippines, during the preceding twelve (12) months (or for such shorter period the registrant was required to file such reports)

Yes [✓] No []

(b) has been subject to such filing requirements for the past ninety (90) days.

Yes [✓] No []

PART I-FINANCIAL INFORMATION

Item 1. Financial Statements.

The unaudited interim financial statements of Allied Care Experts (ACE) Medical Center – Tacloban, Inc. (the Company) as at and for the three months ended March 31, 2026 (with comparative figures as at December 31, 2025 (Audited) and for the three months ended March 31, 2025 (Unaudited) are filed as part of this form 17-Q as Annex A.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

FINANCIAL CONDITION

	31-Mar-2026 (Unaudited)	31-Dec-2025 (Audited)	Horizontal Analysis		Vertical Analysis	
			Inc(Dec)	%age	31-Mar-2026	31-Dec-2025
ASSETS						
Current Assets						
Cash	P 94,241,904	P 83,424,718	P 10,817,186	13%	9%	8%
Trade and other receivables	87,038,599	100,899,223	(13,860,624)	-14%	9%	10%
Inventories	22,343,922	28,222,509	(5,878,587)	-21%	2%	3%
Prepayments and other current assets	14,160,194	8,668,151	5,492,043	63%	1%	1%
Total Current Assets	217,784,619	221,214,601	(3,429,982)	-2%	22%	22%
Non-current Assets						
Property and equipment	772,621,809	780,386,792	(7,764,983)	-1%	77%	77%
Intangible asset	486,607	579,286	(92,679)	-16%	0%	0%
Other noncurrent asset	7,000	7,000	-	0%	0%	0%
Deferred tax asset, net	9,581,933	6,753,619	2,828,314	42%	1%	1%
Total Non-Current Assets	782,697,349	787,726,697	(5,029,348)	-1%	78%	78%
Total Assets	P 1,000,481,968	P 1,008,941,298	(8,459,330)	-1%	100%	100%
LIABILITIES AND EQUITY						
Current Liabilities						
Trade and other payables	P 203,224,719	P 190,916,762	P 12,307,957	6%	20%	19%
Loans payable - current	30,234,467	45,464,286	(15,229,819)	-33%	3%	5%
Advances from shareholders	133,576,496	135,311,988	(1,735,492)	-1%	13%	13%
Total Current Liabilities	367,035,682	371,693,036	(4,657,354)	-1%	37%	37%
Non-Current Liabilities						
Loans payable - non current	213,174,619	213,174,619	-	0%	21%	21%
Total Liabilities	580,210,301	584,867,655	(4,657,354)	-1%	58%	58%
Equity						
Share capital	209,300,000	209,240,000	60,000	0%	21%	21%
Share premium	378,329,000	375,860,000	2,469,000	1%	38%	37%
Revaluation surplus	17,297,193	17,297,193	-	0%	2%	2%
Accumulated deficits	(184,654,526)	(178,323,550)	(6,330,976)	4%	-18%	-18%
Equity, Net	420,271,667	424,073,643	(3,801,976)	-1%	42%	42%
Total Liabilities and Equity	P 1,000,481,968	P 1,008,941,298	(8,459,330)	-1%	100%	100%

As of March 31, 2026, Total assets decreased from P1,000.5M to P1,008.9M. The minimal decrease was primarily due to the decreased in trade and other receivables, inventories, and property and equipment. This was negated by the increased in cash, prepayments and other assets, and deferred tax asset.

The increased in Cash by P10,817,186 was primarily due to the proceeds from issuance of shares and decreased in receivables amounted to P2.5M and P13.9M, respectively. The Company acquired property and equipment amounting to P5.2M and paid principal and interest on loans amounting to P15.2M. These disbursements were funded by the proceeds from issuance, advances from shareholders and cash from operations.

The decreased in trade and other receivables by ₱13.86M were due to collection effort from PhilHealth, MAIP Funds, receivables from patients and reimbursements from HMO and DSWD.

The decrease in inventories by ₱5.88M pertains mainly to the lower purchased in pharmacy and laboratory supplies.

The increased in prepayments and other current assets by ₱5.49M was primarily due to the increased in the prepaid income tax and value added tax on purchases of goods and services partly negated by lower prepaid supplies.

Property and equipment decreased by ₱7.7M. This was primarily due to the depreciation for the period of ₱12.9M negated by the additional office equipment/furniture and fixtures and other hospital equipment of ₱5.2M.

Deferred tax asset increased by ₱2.83M due to the recognition of DTA on MCIT and NOLCO by the Company as of first quarter of 2026 and additional DTA on credit losses.

Total liabilities decreased by ₱4.6M. The decrease was primarily due to payment of loans and trade and other payables which was partly negated by the additional advances from shareholders.

The increase in trade and other payables by ₱12.3M was mainly due to higher purchases made to suppliers of goods and services and settlement of outstanding payables.

The decrease of ₱1.7M on advances from shareholders was due to payment of advances in the first quarter of 2026..

The Company paid ₱15.2M of its loan's payable to Land Bank of the Philippines.

The decreased in equity was primarily due to net loss recognized by the Company as of first quarter of 2026 negated by the increase in share capital and share premium.

Material Changes in Financial Condition

a. Cash increased by ₱10.82M
Primarily due to the proceeds from issuance of shares and decreased in receivables amounted to ₱2.5M and ₱13.9M, respectively. The Company acquired property and equipment amounting to ₱5.2M and paid principal and interest on loans amounting to ₱15.2M. These disbursements were funded by the proceeds from issuance, advances from shareholders and cash from operations.
b. Trade and other receivables decreased by ₱13,86M
Due to collection effort from PhilHealth, MAIP Funds, receivables from patients and reimbursements from HMO and DSWD.
c. Inventories decreased by ₱5.88M
Pertains mainly to the lower purchased in pharmacy and laboratory supplies.
d. Prepayments and other current assets increased by ₱5.49M
Primarily due to the increased in the prepaid income tax and value added tax on purchases of goods and services partly negated by lower prepaid supplies.
e. Property and equipment decreased by ₱7.7M
This was primarily due to the depreciation for the period of ₱12.9M negated by the additional office equipment/furniture and fixtures and other hospital equipment of ₱5.2M.
f. Intangible assets decreased by ₱92,679
Due to amortization recognized in first quarter 2026
g. Deferred tax assets decreased by ₱2.83M
Due to the recognition of DTA on MCIT and NOLCO by the Company as of first quarter of 2026 and additional DTA on credit losses.
h. Trade and other payables decreased by ₱12.3M
Due to higher purchases made to suppliers of goods and services and settlement of outstanding payables.
i. Advances from shareholders decreased by ₱1.7M
due to payment of advances in the first quarter of 2026.
j. Loans payable decreased by ₱15.2M
The Company paid ₱15.2M of its loan's payable to Land Bank of the Philippines.
k. Equity increased by ₱3.8M
Primarily due to net loss recognized by the Company as of first quarter of 2026 negated by the increase in share capital and share premium.

RESULTS OF OPERATIONS

The following table shows the consolidated financial highlights of the Company for the three months ended March 31, 2026:

	For the three months ended		Horizontal Analysis		Vertical Analysis	
	31-Mar-26	31-Mar-25	Inc (Dec)	%age	31-Mar-26	31-Mar-25
Revenue	₱ 130,689,661	₱ 141,579,288	₱ (10,889,627)	-8%	100%	100%
Cost of sales and services	(96,528,546)	(90,295,934)	6,232,612	7%	-74%	-64%
Other income	1,698,376	3,226,485	(1,528,109)	-47%	1%	2%
Operating expenses	(31,442,900)	(32,921,574)	(1,478,674)	-4%	-24%	-23%
Finance costs	(12,858,762)	(9,542,016)	3,316,746	35%	-10%	-7%
Income tax benefit (expense)	2,111,194	(3,011,541)	5,122,735	-170%	2%	-2%
Net income (loss)	₱ (6,330,977)	₱ 9,034,708	₱ (15,365,685)	-170%	-5%	6%

The revenue for the three months ended March 31, 2026 is lower by 8% from the 2025 revenue of ₱141.6M, this was due to decrease in hospital fees and sale of drugs and medicines.

Cost of sales and services for the period ending March 31, 2026 are higher than March 31, 2025 by 7%. This is primarily due to increase of most expenses.

Other income decreased by 47%. This is primarily due to decrease in income from cafeteria as of first quarter of 2026.

4. Leverage b. Debt to total asset ratio - the proportion of total assets financed by creditors. (total debt / total assets) c. Asset to equity ratio - indicator of the overall financial stability of the Company. (total assets / equity)	0.58:1 2.38:1	0.58:1 2.40:1
5. Interest Rate Coverage Ratio a. Interest rate coverage ratio - measure of the company's ability to meet its interest payments (earnings before interest and taxes / interest expense)	0.343:1	2.262:1

DISCUSSION AND ANALYSIS OF MATERIAL EVENTS AND UNCERTAINTIES

There were no material events that would trigger direct or indirect contingent financial obligation that would materially affect the company's operation, including any default or acceleration of obligation.

The Company did not enter into any material off-balance sheet transactions, arrangements, obligations (including contingent obligations), and other relationships with unconsolidated entities or other persons during the period.

There were no any known trends or any known demands, commitments, events or uncertainties that would result in or that were reasonably likely to result in the Company's liquidity increase or decreasing in any material way.

The Company continues to spend for regular capital expenditures during the quarter as disclosed in Note 10 of the unaudited interim financial statements.

There were no known trends, events or uncertainties that have had or that are reasonably expected to have a material favorable or unfavorable impact on net sales or revenues or income from continuing operations.

There were no significant elements of income or loss that did not arise from the Company's continuing operations.

There were no seasonal aspects that had any material effect on the financial condition or results of operations of the Company.

There were no material events subsequent to the end of the interim period that have not been reflected in the financial adjustments of the interim period.

The Company is not a party to any lawsuit or claims arising from the ordinary course of business

PART II--OTHER INFORMATION

There are no additional material information to be disclosed which were not previously reported under SEC Form 17-C


SIGNATURES

Pursuant to the requirements of the Securities Regulation Code, the issuer has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Allied Care Experts (ACE) Medical Center-Tacloban, Inc.

By:


FERNANDO P. CARLOS
President


MICHAEL EDWARD ENRIQUEZ
Treasurer

Date: May 8, 2026

Date: May 8, 2026